Phibro Animal Health Corporation (PAHC)
USD 19.48
(4.73%)
USD 19.48
(4.73%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 53.31 Million USD | -25.79% |
| 2023 | 71.84 Million USD | 55.19% |
| 2022 | 46.29 Million USD | 7.63% |
| 2021 | 43.01 Million USD | 16.7% |
| 2020 | 36.85 Million USD | -49.72% |
| 2019 | 73.3 Million USD | -25.88% |
| 2018 | 98.9 Million USD | 1.02% |
| 2017 | 97.9 Million USD | 14.24% |
| 2016 | 85.7 Million USD | -2.24% |
| 2015 | 87.66 Million USD | 37.41% |
| 2014 | 63.8 Million USD | 12.46% |
| 2013 | 56.73 Million USD | 15.01% |
| 2012 | 49.32 Million USD | 19.62% |
| 2011 | 41.23 Million USD | -21.9% |
| 2010 | 52.8 Million USD | 27.54% |
| 2009 | 41.4 Million USD | 41.3% |
| 2008 | 29.3 Million USD | 38.86% |
| 2007 | 21.1 Million USD | -8.26% |
| 2006 | 23 Million USD | 422.73% |
| 2005 | 4.4 Million USD | -89.93% |
| 2004 | 43.7 Million USD | 68.73% |
| 2003 | 25.9 Million USD | 144.34% |
| 2002 | 10.6 Million USD | 96.3% |
| 2001 | 5.4 Million USD | -65.61% |
| 2000 | 15.7 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 20.19 Million USD | 28.59% |
| 2024 Q4 | 12.63 Million USD | -37.4% |
| 2024 Q2 | 15.7 Million USD | 2343.0% |
| 2024 FY | 62.41 Million USD | -13.12% |
| 2024 Q1 | -700 Thousand USD | -102.95% |
| 2023 Q2 | 15.84 Million USD | 15.78% |
| 2023 Q4 | 23.76 Million USD | 135.05% |
| 2023 Q3 | 10.11 Million USD | -36.18% |
| 2023 FY | 71.84 Million USD | 55.19% |
| 2023 Q1 | 13.68 Million USD | -5.6% |
| 2022 Q2 | 22.29 Million USD | 52.57% |
| 2022 FY | 46.29 Million USD | 7.63% |
| 2022 Q4 | 14.49 Million USD | -24.48% |
| 2022 Q3 | 19.19 Million USD | -13.91% |
| 2022 Q1 | 14.61 Million USD | -23.9% |
| 2021 Q3 | 20.13 Million USD | 1.22% |
| 2021 Q4 | 19.2 Million USD | -4.63% |
| 2021 Q2 | 19.89 Million USD | 26.78% |
| 2021 Q1 | 15.68 Million USD | -13.33% |
| 2021 FY | 43.01 Million USD | 16.7% |
| 2020 Q4 | 18.1 Million USD | -15.1% |
| 2020 FY | 36.85 Million USD | -49.72% |
| 2020 Q1 | 10.14 Million USD | -16.14% |
| 2020 Q2 | 19.6 Million USD | 93.25% |
| 2020 Q3 | 21.31 Million USD | 8.72% |
| 2019 FY | 73.3 Million USD | -25.88% |
| 2019 Q2 | 25.7 Million USD | 12.48% |
| 2019 Q3 | 22.56 Million USD | -12.21% |
| 2019 Q4 | 12.1 Million USD | -46.38% |
| 2019 Q1 | 22.85 Million USD | -12.44% |
| 2018 Q2 | 23.93 Million USD | 6.93% |
| 2018 Q1 | 22.38 Million USD | -4.74% |
| 2018 FY | 98.9 Million USD | 1.02% |
| 2018 Q4 | 26.1 Million USD | -1.48% |
| 2018 Q3 | 26.49 Million USD | 10.67% |
| 2017 Q3 | 29.97 Million USD | 32.46% |
| 2017 Q1 | 21.81 Million USD | 8.52% |
| 2017 FY | 97.9 Million USD | 14.24% |
| 2017 Q4 | 23.5 Million USD | -21.6% |
| 2017 Q2 | 22.62 Million USD | 3.74% |
| 2016 FY | 85.7 Million USD | -2.24% |
| 2016 Q4 | 20.1 Million USD | -5.06% |
| 2016 Q3 | 21.17 Million USD | -6.41% |
| 2016 Q2 | 22.62 Million USD | 3.49% |
| 2016 Q1 | 21.85 Million USD | 4.27% |
| 2015 Q3 | 21.81 Million USD | 10.24% |
| 2015 FY | 87.66 Million USD | 37.41% |
| 2015 Q2 | 19.78 Million USD | -21.18% |
| 2015 Q4 | 20.96 Million USD | -3.9% |
| 2015 Q1 | 25.1 Million USD | 91.64% |
| 2014 Q2 | 17.01 Million USD | 3.79% |
| 2014 Q4 | 13.1 Million USD | -24.37% |
| 2014 Q1 | 16.39 Million USD | 10.01% |
| 2014 Q3 | 17.32 Million USD | 1.79% |
| 2014 FY | 63.8 Million USD | 12.46% |
| 2013 Q3 | 14.46 Million USD | 2.15% |
| 2013 Q2 | 14.15 Million USD | 3.46% |
| 2013 Q4 | 14.9 Million USD | 3.07% |
| 2013 Q1 | 13.68 Million USD | 0.0% |
| 2013 FY | 56.73 Million USD | 15.01% |
| 2012 FY | 49.32 Million USD | 19.62% |
| 2011 FY | 41.23 Million USD | -21.9% |
| 2010 Q2 | 14.8 Million USD | 23.33% |
| 2010 Q1 | 12 Million USD | 148.19% |
| 2010 FY | 52.8 Million USD | 27.54% |
| 2009 Q4 | -24.9 Million USD | -466.18% |
| 2009 Q3 | 6.8 Million USD | -30.61% |
| 2009 Q2 | 9.8 Million USD | -3.92% |
| 2009 FY | 41.4 Million USD | 41.3% |
| 2009 Q1 | 10.2 Million USD | -23.88% |
| 2008 Q4 | 13.4 Million USD | 770.0% |
| 2008 Q2 | 9.6 Million USD | 15.66% |
| 2008 Q1 | 8.3 Million USD | -22.43% |
| 2008 FY | 29.3 Million USD | 38.86% |
| 2008 Q3 | -2 Million USD | -120.83% |
| 2007 FY | 21.1 Million USD | -8.26% |
| 2007 Q4 | 10.7 Million USD | 52.86% |
| 2007 Q2 | 10.9 Million USD | 245.33% |
| 2007 Q1 | -7.5 Million USD | -188.24% |
| 2007 Q3 | 7 Million USD | -35.78% |
| 2006 Q2 | 3.5 Million USD | -14.63% |
| 2006 Q3 | 6.9 Million USD | 97.14% |
| 2006 Q4 | 8.5 Million USD | 23.19% |
| 2006 FY | 23 Million USD | 422.73% |
| 2006 Q1 | 4.1 Million USD | 127.78% |
| 2005 Q2 | -3.3 Million USD | -152.38% |
| 2005 FY | 4.4 Million USD | -89.93% |
| 2005 Q4 | 1.8 Million USD | 5.88% |
| 2005 Q1 | 6.3 Million USD | 117.24% |
| 2005 Q3 | 1.7 Million USD | 151.52% |
| 2004 Q3 | 6.7 Million USD | -76.74% |
| 2004 FY | 43.7 Million USD | 68.73% |
| 2004 Q1 | 5.4 Million USD | -14.29% |
| 2004 Q2 | 28.8 Million USD | 433.33% |
| 2004 Q4 | 2.9 Million USD | -56.72% |
| 2003 Q1 | 6.3 Million USD | 0.0% |
| 2003 Q3 | 5.5 Million USD | -29.49% |
| 2003 Q4 | 6.3 Million USD | 14.55% |
| 2003 FY | 25.9 Million USD | 144.34% |
| 2003 Q2 | 7.8 Million USD | 23.81% |
| 2002 FY | 10.6 Million USD | 96.3% |
| 2001 FY | 5.4 Million USD | -65.61% |
| 2000 FY | 15.7 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | -13.506% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 453.033% |
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 68.067% |
| Cosmos Health Inc. | -21.83 Million USD | 344.215% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 365.909% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 134.272% |
| Cronos Group Inc. | -81.37 Million USD | 165.517% |
| Incannex Healthcare Limited | -30.04 Million USD | 277.474% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 236.171% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | -471.375% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 1225.566% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1214.141% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 1214.141% |
| SCYNEXIS, Inc. | 72.66 Million USD | 26.633% |
| Safety Shot Inc | -12.18 Million USD | 537.577% |
| Theratechnologies Inc. | -10.62 Million USD | 601.694% |
| Alpha Teknova, Inc. | -35.56 Million USD | 249.917% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 1611.721% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 39.19% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 1234.12% |
| Dynavax Technologies Corporation | -37.02 Million USD | 243.986% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 74.495% |
| Radius Health, Inc. | -3.92 Million USD | 1458.344% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 2219.698% |
| Alvotech | -354.86 Million USD | 115.024% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 133.451% |
| SIGA Technologies, Inc. | 83.62 Million USD | 36.242% |
| Shineco, Inc. | -17.06 Million USD | 412.407% |
| Silver Spike Investment Corp. | 7.34 Million USD | -626.352% |
| Journey Medical Corporation | -2.07 Million USD | 2671.877% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 491.522% |
| Embecta Corp. | 221.5 Million USD | 75.93% |
| Harrow Health, Inc. | 580 Thousand USD | -9092.241% |
| Procaps Group, S.A. | 38.97 Million USD | -36.8% |
| Biofrontera Inc. | -22.67 Million USD | 335.106% |
| DURECT Corporation | -36.88 Million USD | 244.548% |
| PainReform Ltd. | -9.58 Million USD | 656.292% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 1111.862% |
| OptiNose, Inc. | -22.74 Million USD | 334.372% |
| RedHill Biopharma Ltd. | 12.63 Million USD | -322.063% |
| Organogenesis Holdings Inc. | 12.52 Million USD | -325.669% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 958.421% |
| ProPhase Labs, Inc. | -21.61 Million USD | 346.68% |
| Procaps Group S.A. | 52.32 Million USD | -1.894% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 725.543% |
| Viatris Inc. | 766.2 Million USD | 93.042% |
| Rockwell Medical, Inc. | -6.67 Million USD | 899.325% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 1114.751% |
| Tilray Brands, Inc. | -174.74 Million USD | 130.51% |
| PetIQ, Inc. | 60.01 Million USD | 11.164% |
| Talphera, Inc. | -16.88 Million USD | 415.679% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 78.75% |
| Alimera Sciences, Inc. | -1.47 Million USD | 3724.405% |
| Assertio Holdings, Inc. | -243.53 Million USD | 121.892% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 1004.813% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 138.676% |
| Hempacco Co., Inc. | -8.81 Million USD | 705.008% |
| Alvotech | -354.86 Million USD | 115.024% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 85.379% |
| Kamada Ltd. | 10.06 Million USD | -429.76% |
| Currenc Group, Inc. | -6.64 Million USD | 902.238% |
| Indivior PLC | -4 Million USD | 1432.875% |
| Evoke Pharma, Inc. | -7.43 Million USD | 817.478% |
| Flora Growth Corp. | -50.35 Million USD | 205.88% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 365.909% |
| Evolus, Inc. | -49.23 Million USD | 208.291% |
| HUTCHMED (China) Limited | 18.37 Million USD | -190.15% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 72.935% |
| Akanda Corp. | -10.05 Million USD | 630.425% |